Page 139 - 南京医科大学自然版
P. 139
第45卷第12期 戴 丽,左祥林,胡 君. 鞘氨醇⁃1⁃磷酸信号通路在微循环障碍相关性心脏疾病中的作用及
2025年12月 治疗潜力[J]. 南京医科大学学报(自然科学版),2025,45(12):1810-1822 ·1821 ·
1551 Cell Death Discov,2023,9(1):380
[52] GERGELY P,NUESSLEIN⁃HILDESHEIM B,GUERINI [63]RAZA Z,SALEEM U,NAUREEN Z. Sphingosine 1⁃phos⁃
D,et al. The selective sphingosine 1⁃phosphate receptor phate signaling in ischemia and reperfusion injury[J].
modulator BAF312 redirects lymphocyte distribution and Prostaglandins Other Lipid Mediat,2020,149:106436
has species⁃specific effects on heart rate[J]. Br J Pharma⁃ [64] LI Q,CHEN B,ZENG C,et al. Differential activation of
col,2012,167(5):1035-1047 receptors and signal pathways upon stimulation by different
[53]VALIŠ M,ACHIRON A,HARTUNG H P,et al. The bene⁃ doses of sphingosine⁃1⁃phosphate in endothelial cells[J].
fits and risks of switching from fingolimod to siponimod Exp Physiol,2015,100(1):95-107
for the treatment of relapsing ⁃ remitting and secondary [65]FREJ C,ANDERSSON A,LARSSON B,et al. Quantifica⁃
progressive multiple sclerosis[J]. Drugs R D,2023,23 tion of sphingosine 1⁃phosphate by validated LC⁃MS/MS
(4):331-338 method revealing strong correlation with apolipoprotein M
[54]CREE B A,ARNOLD D L,FOX R J,et al. Long⁃term in plasma but not in serum due to platelet activation
efficacy and safety of siponimod in patients with secondary during blood coagulation[J]. Anal Bioanal Chem,2015,
progressive multiple sclerosis:analysis of EXPAND core 407(28):8533-8542
and extension data up to >5 years[J]. Mult Scler,2022, [66]HE W S,CUI J Y,WANG X Y,et al. Early⁃stage pancre⁃
28(10):1591-1605 atic cancer diagnosis:serum biomarkers and the potential
[55]SCOTT F L,CLEMONS B,BROOKS J,et al. Ozanimod for aptamer ⁃ based biosensors[J]. Molecules,2025,30
(RPC1063)is a potent sphingosine⁃1⁃phosphate receptor⁃ (9):2012
1(S1P1)and receptor⁃5(S1P5)agonist with autoimmune [67] LI S,SHEN Q L,ZHANG S H. Spatial transcriptomics⁃
disease⁃modifying activity[J]. Br J Pharmacol,2016,173 aided localization for single ⁃ cell transcriptomics with
(11):1778-1792 STALocator[J]. Cell Syst,2025,16(2):101195
[56] COHEN J A,COMI G,SELMAJ K W,et al. Safety and [68]NGUYEN Q,TUNG L W,LIN B,et al. Spatial transcrip⁃
efficacy of ozanimod versus interferon beta⁃1a in relapsing tomics in human cardiac tissue[J]. Int J Mol Sci,2025,26
multiple sclerosis(RADIANCE):a multicentre,ran⁃ (3):995
domised,24 ⁃ month,phase 3 trial[J]. Lancet Neurol, [69]XU Z M,IKUTA T,KAWAKAMI K,et al. Structural basis
2019,18(11):1021-1033 of sphingosine ⁃ 1 ⁃ phosphate receptor 1 activation and
[57] LOTT D,LEHR T,DINGEMANSE J,et al. Modeling biased agonism[J]. Nat Chem Biol,2022,18(3):281-
tolerance development for the effect on heart rate of the 288
selective S1P1 receptor modulator ponesimod[J]. Clin [70]MAEDA S,SHIIMURA Y,ASADA H,et al. Endogenous
Pharmacol Ther,2018,103(6):1083-1092 agonist⁃bound S1PR3 structure reveals determinants of G
[58] SANDBORN W J,VERMEIRE S,PEYRIN⁃BIROULET protein⁃subtype bias[J]. Sci Adv,2021,7(24):eabf5325
L,et al. Etrasimod as induction and maintenance therapy [71] TOYOMOTO M,INOUE A,IIDA K,et al. S1PR3⁃G12⁃
for ulcerative colitis(ELEVATE):two randomised,double⁃ biased agonist ALESIA targets cancer metabolism and
blind,placebo ⁃ controlled,phase 3 studies[J]. Lancet, promotes glucose starvation[J]. Cell Chem Biol,2021,28
2023,401(10383):1159-1171 (8):1132-1144
[59]WU X K,XU J W,LI X Y,et al. Inhibition of SphK1/S1P [72]GAIDAROV I,KOMORI H K,STEPNIAK D T,et al.
signaling pathway alleviates fibrosis and inflammation of Unique pharmacological properties of etrasimod among
rat myocardium after myocardial infarction[J]. Comput S1P receptor modulators[J]. FEBS Open Bio,2025,15
Math Methods Med,2022,2022:5985375 (1):108-121
[60]ZHANG F Y,XIA Y L,YAN W J,et al. Sphingosine 1⁃ [73]CASTRO R,ADAIR J H,MASTRO A M,et al. VCAM⁃1⁃
phosphate signaling contributes to cardiac inflammation, targeted nanoparticles to diagnose,monitor and treat
dysfunction,and remodeling following myocardial infarc⁃ atherosclerosis[J]. Nanomedicine(Lond),2024,19(8):
tion[J]. Am J Physiol Heart Circ Physiol,2016,310(2): 723-735
H250-H261 [74] LV X F,ZHANG C,SHUAIZHEN Q Y,et al. Design of
[61] SANTOS W L ,LYNCH K R. Drugging sphingosine integrin αvβ3 targeting self⁃assembled protein nanoparti⁃
kinases[J]. ACS Chem Biol,2015,10(1):225-233 cles with RGD peptide[J]. Biomed Pharmacother,2020,
[62]XIAO S Q,PENG K X,LI C X,et al. The role of sphingo⁃ 128:110236
sine⁃1⁃phosphate in autophagy and related disorders[J]. [75] WILLIAMS P A,CAMPBELL K T,GHARAVIRAM H,

